FDA Approves Bayer’s SUNHARBO for Secondary Stroke Prevention
The FDA approved SUNHARBO (asundexian) with antiplatelet therapy to reduce recurrent stroke risk in eligible adults, according to Bayer.
LEVERKUSEN (dpa-AFX) - Bayer AG (BAYN.DE, BYR.L) announced that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO (asundexian) in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS?15) or high-risk trans…